alanine has been researched along with Lymphoma in 19 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rabacfosadine (RAB, Tanovea-CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs." | 9.51 | Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma. ( Avery, AC; Bergman, PJ; Christman Hull, AA; Clifford, CA; Donoghue, AR; Gust, CM; McDaniel, JA; Phillips, BS; Post, GS; Randall, EK; Rosenberg, MP; Thamm, DH; Weishaar, KM; Wright, ZM, 2022) |
| "Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs." | 7.96 | Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. ( Bergman, PJ; Cawley, JR; Clifford, CA; Meleo, K; Post, GS; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2020) |
| " Response assessment and adverse event (Ae) evaluation were performed every 21 days via Veterinary Cooperative Oncology Group (VCOG) criteria." | 6.94 | Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. ( Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020) |
| "Rabacfosadine (RAB, Tanovea-CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs." | 5.51 | Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma. ( Avery, AC; Bergman, PJ; Christman Hull, AA; Clifford, CA; Donoghue, AR; Gust, CM; McDaniel, JA; Phillips, BS; Post, GS; Randall, EK; Rosenberg, MP; Thamm, DH; Weishaar, KM; Wright, ZM, 2022) |
| "Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs." | 4.98 | Tanovea® for the treatment of lymphoma in dogs. ( De Clercq, E, 2018) |
| "Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs." | 3.96 | Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. ( Bergman, PJ; Cawley, JR; Clifford, CA; Meleo, K; Post, GS; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2020) |
| " Response assessment and adverse event (Ae) evaluation were performed every 21 days via Veterinary Cooperative Oncology Group (VCOG) criteria." | 2.94 | Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. ( Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (47.37) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Weishaar, KM | 1 |
| Wright, ZM | 2 |
| Rosenberg, MP | 1 |
| Post, GS | 3 |
| McDaniel, JA | 1 |
| Clifford, CA | 2 |
| Phillips, BS | 2 |
| Bergman, PJ | 2 |
| Randall, EK | 1 |
| Avery, AC | 1 |
| Thamm, DH | 3 |
| Christman Hull, AA | 1 |
| Gust, CM | 1 |
| Donoghue, AR | 1 |
| Kajova, M | 1 |
| Kekäläinen, E | 1 |
| Anttila, VJ | 1 |
| Paajanen, J | 1 |
| Cawley, JR | 1 |
| Meleo, K | 1 |
| Vickery, KR | 1 |
| Vail, DM | 2 |
| Saba, CF | 1 |
| Clifford, C | 1 |
| Burgess, K | 1 |
| Phillips, B | 1 |
| Vail, D | 1 |
| Wright, Z | 1 |
| Curran, K | 1 |
| Fan, T | 1 |
| Elmslie, R | 1 |
| Post, G | 1 |
| Thamm, D | 1 |
| Fan, TM | 1 |
| Axiak-Bechtel, S | 1 |
| Elmslie, RS | 1 |
| Klein, MK | 1 |
| Ruslander, DA | 1 |
| De Clercq, E | 1 |
| Pulka-Ziach, K | 1 |
| Pavet, V | 1 |
| Chekkat, N | 1 |
| Estieu-Gionnet, K | 1 |
| Rohac, R | 1 |
| Lechner, MC | 1 |
| Smulski, CR | 1 |
| Zeder-Lutz, G | 1 |
| Altschuh, D | 1 |
| Gronemeyer, H | 1 |
| Fournel, S | 1 |
| Odaert, B | 1 |
| Guichard, G | 1 |
| HRUBAN, Z | 2 |
| WISSLER, RW | 2 |
| SAMAL, BA | 1 |
| FRAZIER, LE | 1 |
| MONTO, G | 1 |
| SLESERS, A | 1 |
| DIETRICH, FS | 1 |
| COPE, C | 1 |
| RIVERS, S | 1 |
| KRANTZ, S | 1 |
| BAUM, G | 1 |
| BECK, HJ | 1 |
| RODENSKY, PL | 1 |
| KIT, S | 2 |
| GREENBERG, DM | 2 |
| Fox, BW | 1 |
| Fox, M | 1 |
| Nguyen, BT | 1 |
| El Sayed, YM | 1 |
| Sadée, W | 1 |
| Erbeznik, H | 1 |
| Hersh, LB | 1 |
| Cuff, JM | 1 |
| Lichtman, MA | 1 |
| Goffin, V | 1 |
| Norman, M | 1 |
| Martial, JA | 1 |
| Buc-Calderon, P | 1 |
| Defresne, MP | 1 |
| Barvais, C | 1 |
| Roberfroid, M | 1 |
1 review available for alanine and Lymphoma
| Article | Year |
|---|---|
Tanovea® for the treatment of lymphoma in dogs.
Topics: Alanine; Animals; Antineoplastic Agents; Dogs; Lymphoma; Prodrugs; Purines; Treatment Outcome | 2018 |
2 trials available for alanine and Lymphoma
| Article | Year |
|---|---|
Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lymphoma; Puri | 2022 |
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Topics: Alanine; Animals; Dog Diseases; Dogs; Female; Lymphoma; Male; Purines; Treatment Outcome | 2020 |
16 other studies available for alanine and Lymphoma
| Article | Year |
|---|---|
Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient.
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Humans; Lymphoma; SARS-CoV-2 | 2022 |
Topics: Alanine; Animals; Dog Diseases; Dogs; Lymphoma; Purines | 2022 |
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Topics: Alanine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2020 |
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Topics: Alanine; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Doxorubicin; Drug Administration Schedu | 2017 |
Thioether analogues of disulfide-bridged cyclic peptides targeting death receptor 5: conformational analysis, dimerisation and consequences for receptor activation.
Topics: Alanine; Antineoplastic Agents; Apoptosis; Chemistry Techniques, Synthetic; Dimerization; Disulfides | 2015 |
Effect of beta-3-thienylalanine and deoxypyridoxine on the growth of the Murphy-Sturm lymphosarcoma.
Topics: Alanine; Antineoplastic Agents; Lymphoma; Lymphoma, Non-Hodgkin; Testosterone; Vitamin B 6 | 1960 |
Distribution of tritium labeled beta-3-thienyl-L-alanine in tissues of adult male rats bearing Murphy-Sturm lymphosarcoma.
Topics: Alanine; Animals; beta-Alanine; Lymphoma; Lymphoma, Non-Hodgkin; Male; Phenylalanine; Rats; Tritium | 1963 |
Clinical trial with alanine mustard.
Topics: Alanine; Lung Neoplasms; Lymphoma; Mustard Plant; Nitrogen Mustard Compounds; Stomach Neoplasms | 1962 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells.
Topics: Alanine; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Radioactive Tracers; Sarcoma; Spleen | 1951 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. IV. The conversion of lactate-2-C14 to alanine, glutamate, and aspartate by tumor and spleen cells.
Topics: Alanine; Aspartic Acid; Glutamates; Glutamic Acid; Lactic Acid; Lymphoma; Lymphoma, Non-Hodgkin; Neo | 1951 |
Effect of methyl methanesulfonate on macromolecular biosynthesis in P388F cells.
Topics: Alanine; Animals; Culture Techniques; DNA, Neoplasm; Glycine; Lymphoma; Mice; Neoplasm Proteins; Neo | 1967 |
Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells.
Topics: Adenine; Adenosine; Alanine; Animals; Antimetabolites, Antineoplastic; Cell Division; DNA Replicatio | 1984 |
A novel mammalian high-molecular-weight aminopeptidase.
Topics: Alanine; Amides; Aminopeptidases; Arginine; Brain; Chromatography, Gel; Enzyme Inhibitors; Humans; I | 1997 |
Adaptation of potassium metabolism and restoration of mitosis during prolonged treatment of mouse lymphoblasts with ouabain.
Topics: Adaptation, Physiological; Alanine; Animals; Cells, Cultured; Cycloheximide; Dactinomycin; DNA, Neop | 1975 |
Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity.
Topics: Alanine; Amino Acid Sequence; Base Sequence; Cell Division; Growth Hormone; Humans; Lymphoma; Molecu | 1992 |
N-acyl dehydroalanines protect from radiation toxicity and inhibit radiation carcinogenesis in mice.
Topics: Alanine; Amifostine; Animals; Female; Free Radicals; Hydroxides; Hydroxyl Radical; Lymphoma; Mice; M | 1989 |